INS and Hypoglycemia: This might be explained by the mechanisms through which tirzepatide lowers blood glucose: it stimulates glucose-dependent insulin release from pancreatic β-cells, resulting in a minimal risk of hypoglycemia when used alone [28].Our meta-analysis further found that treatment with tirzepatide did not increase the incidence of SAEs or lead to an increase in all-cause mortality.